Monthly research recap
Ayahuasca research: September 2026
What September 2026's 8 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research indexed or published in 2026 on ayahuasca is mostly preliminary and points in a broadly favorable direction: a small uncontrolled pilot in cancer patients found reductions in depression and anxiety lasting up to three weeks after a single dose, an observational survey linked greater prior ayahuasca experience to better mental health, and a single dose reduced stress-related behavioral and neurochemical changes in rats. However, the human evidence rests on very small, uncontrolled or cross-sectional samples, and reviews emphasize that trials are limited by strict selection, blinding difficulties, and ethical gaps; a narrative review also notes that psychotic reactions, while uncommon in screened or supervised settings, can occur in vulnerable individuals.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psychosis associated with ayahuasca: A narrative review of traditional use, vulnerability, and case evidence 2026 | narrative review | Mixed | Argues that ayahuasca is not a robust inducer of persistent psychosis in culturally embedded or clinically supervised use, but that psychotic or manic episodes can occur in vulnerable individuals, particularly in unsupervised or adulterated settings. | |
| Unveiling ayahuasca: Comprehensive Study of Botanical and Chemical Diversity. 2026 | narrative review | Unclear | Reports that ayahuasca involves greater botanical diversity than commonly recognized, identifying 24 vine and 13 leaf species, of which five vine and four leaf species were classified as historically confirmed ingredients. | |
| “She Told Me So”: Psychoanalytic Perspectives on the Plant Third and the Messages from Ayahuasca 2026 | theoretical or philosophical paper | Unclear | Argues that the ayahuasca 'plant third' can be illuminated through Lacanian transference and object-relations concepts while treating it and the analytic third as ontologically incommensurate, with implications for psychotherapy and post-ritual integration. | |
| Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats. 2026 | preclinical animal study (experimental) | Supports | A single ayahuasca dose attenuated anxiety- and depressive-like behaviors and neurochemical changes (BDNF, monoamines, oxidative stress) assessed 15 days after administration. | |
| Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis 2026 | single-blind uncontrolled pilot study | 6 | Supports | A single ayahuasca administration produced significant reductions in depressive and anxiety symptoms lasting up to three weeks, with no serious adverse effects, and greater improvement was associated with more intense subjective psychedelic experiences. |
| Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review 2026 | narrative review | Supports | Reports that psilocybin and ayahuasca both show rapid reductions in depressive symptoms in treatment-resistant depression, with psilocybin having more robust evidence for sustained effects, while noting constraints from strict selection criteria, blinding difficulties, small samples, and ethical gaps. | |
| Prior ayahuasca experience is associated with improved mental health: observational data from ritualistic settings 2026 | observational survey study | Supports | High-experience ayahuasca users reported significantly lower alcohol use, depression, stress, and anxiety and higher spiritual well-being and stronger metaphysical beliefs than less experienced users, while aberrant salience was higher in both experienced groups than in naive users. | |
| Producción científica en Scopus sobre el uso de ayahuasca en la salud humana: Estudio Bibliométrico 2026 | bibliometric study | Unclear | Reports that publications on ayahuasca use in human health increased from 2012 onward, with 36.8% using observational designs and an average of 6.1 citations per article. |
Points of agreement
- Human evidence points toward reductions in depressive and anxiety symptoms after ayahuasca, though samples are small and mostly uncontrolled.
- Ayahuasca is generally described as safe in screened or supervised settings, with serious adverse events not reported in the pilot study.
- Reviews agree that current clinical evidence is limited by small samples, selection criteria, and blinding difficulties.
Conflicts
- One review notes that ayahuasca is not a robust inducer of persistent psychosis in supervised use, while also documenting psychotic or manic episodes in vulnerable individuals, indicating that risk depends on context and vulnerability.
- One review reports more robust evidence for sustained antidepressant effects with psilocybin than with ayahuasca, whereas other studies report sustained ayahuasca effects up to three weeks.
Gaps
- Lack of placebo-controlled and adequately powered human trials.
- Durability of effects beyond three weeks is largely unexamined in the human studies.
- Blinding is difficult and often incomplete in psychedelic trials.
- Populations studied are narrow, including only female cancer patients in one pilot and self-selected ceremony attendees in the survey.
- Dose, preparation composition, and botanical variability are not standardized across studies.
- Long-term psychiatric risk in vulnerable individuals remains poorly characterized.